News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Silica is a proven and highly effective anti-caking agent that has been used for decades
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Subscribe To Our Newsletter & Stay Updated
